Cancer Dictionary · Genitourinary

Bladder and Urothelial Cancer

Whether the tumour has invaded the muscle layer of the bladder wall separates two almost entirely different management conversations. Non-muscle-invasive disease is a long-term surveillance and local treatment problem. Muscle-invasive and metastatic disease is where systemic treatment and molecular profiling enter. Upper tract disease is a third situation again, with its own inherited-risk question.

Also called Urothelial carcinoma, Transitional cell carcinoma, Upper tract urothelial carcinoma.

Browse all entries Ask a question, free

Start here

The governing idea

Urothelial cancer is divided by depth of invasion, and this division governs the entire management discussion. Molecular profiling has become relevant in advanced disease.

01Before any molecular question

How it usually presents

Usually established first: whether the tumour is non-muscle-invasive or muscle-invasive, grade, and whether the disease is in the bladder or the upper tract. The depth of invasion comes from the resection specimen, and whether that specimen included muscle is itself a recognised quality question, because a specimen without muscle cannot establish that muscle is uninvolved.

Usually already established

Depth of invasion, and whether the resection specimen contained muscle
Grade and any variant histology
Site: bladder, renal pelvis or ureter
Renal function, which constrains systemic treatment options

Major disease categories

The divisions below are not labels. Each one changes what the treatment discussion is actually about.

Non-muscle-invasive bladder cancer

Managed with local treatment and long-term surveillance. Recurrence is common; progression to muscle-invasive disease is the outcome the surveillance is designed to catch.

Muscle-invasive bladder cancer

A different disease in management terms. Systemic treatment around definitive local treatment organises the discussion.

Metastatic urothelial carcinoma

The setting where molecular profiling most changes the treatment discussion.

Upper tract urothelial carcinoma

Disease in the renal pelvis or ureter. Managed differently, and with a materially higher association with Lynch syndrome.

03What is discussed

Molecular considerations

FGFR3 alterations, ERBB2 alterations, high tumour mutational burden and PD-L1 expression are among the features assessed in advanced disease. Nectin-4 and TROP-2 expression are relevant to antibody-drug conjugate research. FGFR3 alterations are considerably more common in non-muscle-invasive and upper tract disease than in muscle-invasive disease, so where the sample came from affects what is likely to be found. TP53 and RB1 alterations are frequent in muscle-invasive disease. Molecular subtypes such as luminal and basal are a research classification rather than routine reporting.

Biomarkers commonly discussed

FGFR3

Alterations, including fusions. More common in non-muscle-invasive and upper tract disease.

ERBB2 (HER2)

Alterations and amplification, of increasing therapeutic interest.

PD-L1

Assessed in advanced disease as part of the immune treatment discussion.

TMB

Urothelial carcinoma tends to carry a relatively high mutational burden.

MMR / MSI

Uncommon, but relevant, and connected to the Lynch syndrome question in upper tract disease.

Nectin-4

A surface target relevant to antibody-drug conjugate approaches.

TROP-2

Another surface target in the same class of research.

This is not an exhaustive list, and which markers are relevant depends on the individual case. Not every marker listed is assessed in every patient.

04What is tested, and from what

Testing, inherited risk and blood-based monitoring

Genomic testing considerations

Profiling is widely discussed in advanced urothelial carcinoma. The practical questions are which specimen is used and whether the panel reads fusions, since FGFR3 alterations include fusions as well as point mutations. Archival tissue from an earlier resection is frequently the only material available, and it may not represent current disease. Renal function often limits treatment options in this disease, which makes knowing the alternatives earlier rather than later practically useful.

Germline considerations

Upper tract disease raises the question of Lynch syndrome in some presentations. Upper tract urothelial carcinoma is a recognised Lynch-associated cancer, and in some series a meaningful proportion of cases carry an inherited mismatch repair alteration. Younger age, a personal or family history of colorectal, endometrial or other Lynch-associated cancers, or mismatch repair deficiency on the tumour are the usual prompts.

Cancer genetics and hereditary risk

ctDNA and liquid biopsy considerations

ctDNA is under active study for molecular residual disease after cystectomy. This is one of the settings where the question of whether an early molecular signal should change treatment is being tested directly rather than assumed. In advanced disease, plasma is also used where tissue is old or unavailable.

When molecular information matters

Testing that arrives after the decision it was meant to inform has already been made is a common and avoidable problem. This is the sequence in which molecular information tends to become relevant.

At first resectionDepth of invasion is established here, and whether the specimen contained muscle determines whether that answer is reliable.
In non-muscle-invasive diseaseThe discussion is long-term surveillance and local treatment. Molecular profiling is rarely part of routine management.
Before systemic treatment in muscle-invasive diseaseRenal function and fitness shape what is possible. Profiling is discussed more often at the advanced stage.
After cystectomyMolecular residual disease monitoring is under active study rather than settled practice.
In metastatic diseaseFGFR3 status, HER2, PD-L1 and surface target expression all enter the discussion.
In upper tract diseaseThe Lynch syndrome question is worth raising explicitly rather than waiting for a family history to prompt it.

06Take these to your team

Questions worth raising

When a decision is being made

Questions worth raising with a treating team.

Is invasion depth unambiguous, and did the resection specimen include muscle?
Has FGFR3 been assessed in advanced disease, using a panel that reads fusions as well as point mutations?
For upper tract disease, has Lynch syndrome been considered?
Is the tissue being profiled current, or archival material from a resection some time ago?
Has renal function been factored into the treatment discussion, since it constrains several options?

At progression, recurrence or resistance

The molecular picture at diagnosis is not always the molecular picture later.

Has the molecular profile been reassessed after progression?
Has a current sample been used, rather than carrying forward a result from archival tissue?
Have surface target expression and trial options been reviewed at each change of treatment?

07What shapes eligibility

Clinical trial considerations

FGFR3 status and prior therapy strongly shape eligibility. Because urothelial carcinoma has a fast-moving therapeutic landscape, the exact sequence and timing of prior treatment is frequently as decisive as the molecular profile.

Ask about trial matching

Plain-language glossary for this entry (5 terms)

Term	What it means
Non-muscle-invasive	Cancer confined to the inner layers of the bladder wall. Managed locally, with long-term surveillance.
Muscle-invasive	Cancer that has grown into the muscle layer. A different management conversation entirely.
Upper tract	The renal pelvis and ureter, above the bladder. Same cell type, different management, different inherited-risk profile.
Cystectomy	Surgical removal of the bladder.
Antibody-drug conjugate	A treatment that uses an antibody to deliver a drug directly to cells carrying a particular surface marker.

Where OnKommon fits

These are the services most often relevant to this cancer. Which of them applies is a clinical question, not an automatic one.

Signature STb O+The 523-gene comprehensive panel, with TMB and MSI.See how it works HeritageInherited-risk testing, and a tested pathway for relatives.See how it works ClearMolecular residual disease surveillance after curative-intent treatment.See how it works SentinelSerial monitoring during active treatment.See how it works

This entry is educational. It describes what is commonly discussed in this cancer, not what should happen for any individual. Which of it applies depends on the specific diagnosis, stage, prior treatment and the person themselves. Nothing here is a recommendation, and no list of biomarkers here is exhaustive. Decisions belong with a treating team who know the whole case.

Take the next step

Three ways forward. Pick the one that fits today.

Book a free consultation

A no-obligation conversation with our care team, arranged through KPCIRC.

Book a consultation

Begin Blueprint Care

Commission your decision report and a dedicated clinical team.

Explore Blueprint Care

Ask on WhatsApp, free

Signal replies to your first question within four hours, at no cost.

Start with Signal